Document is current
Any future updates will be listed below
-
Authors
Gammel, Michael Christian Marius https://orcid.org/0009-0007-5966-0088
Olufs, Charlotte
Hansen, Kimberley
Brosch-Lenz, Julia
Heck, Matthias
Weber, Wolfgang A.
Eiber, Matthias
Rauscher, Isabel
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 24 January 2026
First Online: 3 February 2026
Declarations
:
: All patients provided written informed consent for the clinical examination and reported investigations were conducted in accordance with the Declaration of Helsinki and with national regulations. The local ethics committee approved the retrospective analysis (permits: 2019-99_2-S-SR, updated on May 31, 2023).
: Not applicable.
: Isabel Rauscher and Matthias Eiber received consulting fees, research funding and travel support from Blue Earth Diagnostics Ltd. Outside the submitted work, Matthias Eiber reports fees from Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker), and Janssen Pharmaceuticals (consultant, speakers bureau); Parexel (image review) and Bioclinica (image review; and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of [ 18 F]F-flotufolastat. Wolfgang A Weber reports research support fees from Blue Earth Diagnostics Ltd, ITM, Novartis, and Pentixapharm. He has also acted as a consultant for these companies. There are no other conflicts of interest to disclose.
